New High-Dose flu vaccine trial aims to better protect seniors
NCT ID NCT07302256
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new influenza vaccine in 120 adults aged 60 and older. Participants receive either a high-dose vaccine, a standard-dose vaccine, or a placebo. The study focuses on safety and how well the vaccine triggers an immune response, with the goal of developing a more effective flu shot for older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Influenza virus split vaccine (high-dose and standard-dose)
What this could lead to
If successful, this could lead to a more effective flu vaccine for older adults, who are at higher risk of severe flu.
What could go wrong
This is a very early Phase 1 trial with only 120 people, so it is primarily checking safety and immune response, not yet proving the vaccine prevents flu. The higher dose may cause more side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Danjiangkou Disease Prevention and Control Center
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••